UDK 61 Медицина. Охрана здоровья
The Janus kinase inhibitors are oral targeted synthetic basic anti-inflammatory drugs that exert their influence on the intracellular signaling system, preventing the activation of inflammatory processes. Now, there are a sufficient number of janus kinase inhibitors that have found application not only in rheumatology, but also in other specialties (gastroenterology, dermatology, hematology, oncology and even veterinary medicine). Thanks to janus kinase inhibitors, suppression of the intracellular signaling pathway of several cytokines simultaneously became available, as a result of which it became possible to exert a complex pathogenic effect. This explains the wide range of applications of these drugs in many areas of medicine. In rheumatology, janus kinase inhibitors are finding new and new applications in the treatment of not only rheumatoid arthritis, but also other diseases. This article presents studies on ankylosing spondylitis and psoriatic arthritis, the results of which demonstrate high rates regarding the use of janus kinase inhibitors for the treatment of these diseases.
targeted synthetic drugs, tofacitinib, filgotinib, upadacitinib, psoriatic arthritis, ankylosing spondylitis, pharmacotearpy.
1. Beloglazov V.A., Goncharov G.S., Shaduro D.V. Ingibitory JANUS-kinaz. Perspektivy i opyt primeneniya v mirovoy klinicheskoy praktike // TMBV. 2018. №4. URL: https://cyberleninka.ru/article/n/ingibitory-janus-kinaz-perspektivy-i-opyt-primeneniya-v-mirovoy-klinicheskoy-praktike;
2. V.I. Mazurov. Malye molekuly v revmatologii: ot innovaciy k praktike;
3. Karateev D.E., Luchihina E.L., Misiyuk A.S. Rossiyskiy i Mezhdunarodnyy opyt primeneniya ingibitora Yanus-kinaz pri revmatoidnom artrite // MS. 2017. №10. URL: https://cyberleninka.ru/article/n/rossiyskiy-i-mezhdunarodnyy-opyt-primeneniya-ingibitora-yanus-kinaz-pri-revmatoidnom-artrite;
4. Maev I.V., Andreev D.N. Targetnaya terapiya vospalitel'nyh zabolevaniy kishechnika: realii i perspektivy // MS. 2018. №6. URL: https://cyberleninka.ru/article/n/targetnaya-terapiya-vospalitelnyh-zabolevaniy-kishechnika-realii-i-perspektivy;
5. E. A. Ortenberg. Ingibitory yanus-kinaz i Covid-19 - mesto v algoritmah farmakoterapii. Tyumenskiy gosudarstvennyy medicinskiy universitet, Tyumen', Rossiya;
6. Nasonov E.L, Lila A.M. Ingibitory Yanus-kinaz pri immunovospalitel'nyh revmaticheskih zabolevaniyah: novye vozmozhnosti i perspektivy. Nauchno-prakticheskaya revmatologiya. 2019;57(1):8-16;
7. Nasonov E.L., Lila A.M. Perspektivy primeneniya upadacitiniba pri revmatoidnyh artritah i drugih immunovospalitel'nyh revmaticheskih zabolevaniyah. // Nauchno-prakticheskaya revmatologiya. 2020. №5. URL: https://cyberleninka.ru/article/n/perspektivy-primeneniya-upadatsitiniba-pri-revmatoidnom-artrite-i-drugih-immunovospalitelnyh-revmaticheskih-zabolevaniyah;
8. Novikov P.I., Shevcova T.P., Schegoleva E.M., Moiseev S.V. Ingibitory yanus-kinaz: farmakologicheskie svoystva i sravnitel'nye klinicheskaya effektivnost' i bezopasnost'. Klin farmakol ter 2021;30(1):51- 60;
9. Shirokova Irina INGIBITORY YaNUS-KINAZ V TERAPII REVMATOIDNOGO ARTRITA - NOVYE VOZMOZhNOSTI I PERSPEKTIVY // Remedium. 2020. №7-8. URL: https://cyberleninka.ru/article/n/ingibitory-yanus-kinaz-v-terapii-revmatoidnogo-artrita-novye-vozmozhnosti-i-perspektivy;
10. Erdes ShF. Poslednie dostizheniya i perspektivy terapii aksial'nogo spondiloartrita / ankiloziruyuschego spondilita. Sovremennaya revmatologiya. 2021;15(2):94-105. DOI:https://doi.org/10.14412/1996-7012-2021-2-94-105;
11. Loginova EYu, Korsakova YuL, Gubar' EE i dr. Effektivnost' i bezopasnost' tofacitiniba u bol'nyh psoriaticheskim artritom v real'noy klinicheskoy praktike. Nauchno-prakticheskaya revmatologiya. 2020;58(3):268-2;
12. Korotaeva TV, Loginova EYu. Rezul'taty izucheniya klinicheskoy effektivnosti i bezopasnosti tofacitiniba v lechenii psoriaticheskogo artrita. Sovremennaya revmatologiya. 2019;13(2):112-118;
13. Nash, Peter et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. The Lancet Rheumatology, Volume 3, Issue 1, e28 - e39;
14. Orbai, Ana-Maria & Ogdie, Alexis & Gossec, Laure & Tillett, William & Leung, Ying Ying & Gao, Jingjing & Trivedi, Mona & Tasset, Chantal & Meuleners, Luc & Besuyen, Robin & Hendrikx, Thijs & Coates, Laura. (2019). Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford, England). 59.https://doi.org/10.1093/rheumatology/kez408;
15. McInnes, Iain & Anderson, Jaclyn & Magrey, Marina & Merola, Joseph & Liu, Yi & Kishimoto, Mitsumasa & Jeka, Slawomir & Pacheco-Tena, Cesar & Wang, Xin & Chen, Liang & Zueger, Patrick & Liu, John & Pangan, Aileen & Behrens, Frank. (2021). Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine. 384. 1227-1239.https://doi.org/10.1056/NEJMoa2022516.
